Depletion of PD-1-positive cells ameliorates autoimmune disease. The targeted depletion of PD-1-expressing cells contingent to the preservation of adaptive immunity might be effective in the treatment of a wide range of autoimmune diseases. Nature Biomedical Engineering, 03/04/2019. (Also see B Cells and T Cells)
Full high–throughput sequencing analysis of differences in expression profiles of long noncoding RNAs and their mechanisms of action in systemic lupus erythematosus. This work determined specific lncRNAs that play important biological functions in the pathogenesis of lupus and provided a new direction for diagnosis and treatment of disease. PubMed, Arthritis Res Ther, 2019 Mar 5;21(1):70. (Also see Research on Systemic Lupus Erythematosus)
Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis (PsA) but not psoriasis. These findings provide insights into the biological mechanisms that are specific for PsA and could contribute to develop more effective therapies. PubMed, Ann Rheum Dis, 2019 Mar;78(3). (Also see Psoriasis and Psoriatic Arthritis)
Dental implants in patients with Sjögren's syndrome (SS): a case series and a systematic review. Dental implants should be considered by dentists as a viable treatment option for patients with SS, as the failure rate is fairly low. PubMed, Int J Oral Maxillofac Surg, 02/28/2019. (Also see Symptoms and Complications of Sjogren's Syndrome and Dental Implants)
Siblings of patients with rheumatoid arthritis (RA) are at increased risk of acute coronary syndrome (ACS). Siblings of patients with RA are at increased risk of ACS, suggesting shared susceptibility between RA and ACS. PubMed, Ann Rheum Dis, 02/20/2019. (Also see Symptoms and Complications of Rheumatoid Arthritis)
Two subgroups in systemic lupus erythematosus (SLE) with features of antiphospholipid (APS) or Sjögren's syndrome (SS) differ in molecular signatures and treatment perspectives. Stratifying SLE patients based on an autoantibody profile could be a way forward to understand underlying pathophysiology and to improve selection of patients for clinical trials of targeted treatments. PubMed, Arthritis Res Ther, 2019 Feb 18;21(1):62. (Also see Lupus in Overlap, Sjögren's Syndrome and Antiphospholipid Syndrome)
Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus (SLE). The data suggest that targeting plasmacytoid DCs may be beneficial for patients with SLE, especially those with cutaneous manifestations. PubMed, J Clin Invest, 2019 Mar 1;129(3):1359-1371. (Also see Antibodies in Lupus)
Prevalence of and factors associated with dysfunctional low back pain in patients with rheumatoid arthritis. Strictly controlling patients' body weight and disease activity with methotrexate and avoiding spinopelvic malalignment through vertebral fracture prevention are important. PubMed, Eur Spine J, 03/08/2019. (Also see Symptoms and Complications of Rheumatoid Arthritis)
Galectin-9 and CXCL10 as biomarkers for disease activity in juvenile dermatomyositis (JDM): a longitudinal cohort study and multi–cohort validation. Galectin-9 and CXCL10 were validated as sensitive and reliable biomarkers for disease activity in (J)DM and implementation of these biomarkers into clinical practice might facilitate personalized treatment strategies. PubMed, Arthritis Rheumatol, 03/12/2019. (Also see Dermatomyositis and Polymyositis)
Early–stage predictors for treatment responses in patients with active lupus nephritis (LN). The change percentage of urinary protein-to-creatinine ratio >59% and the serum albumin >32.9g/l at the third month were valuable for predicting remission at the sixth month in LN. PubMed, Lupus. 2019 Mar;28(3):283-289. (Also see Treatments for Lupus)
TOLL FREE HOTLINE, U.S. and Canada: 1-800-564-7099
Ask for our Free Info Packet by email or postal mail!
SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses.
We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to: